- Report
- October 2024
- 194 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- April 2025
- 196 Pages
Global
From €4692EUR$4,950USD£3,920GBP
- Report
- August 2024
- 175 Pages
Global
From €4739EUR$5,000USD£3,959GBP
- Report
- October 2024
- 184 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- October 2024
- 191 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- January 2025
- 153 Pages
Global
From €5640EUR$5,950USD£4,711GBP
- Report
- March 2025
- 188 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- April 2025
- 197 Pages
Global
From €4692EUR$4,950USD£3,920GBP
- Report
- February 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- February 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- February 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- November 2024
- 120 Pages
Global
From €5640EUR$5,950USD£4,711GBP
- Report
- March 2025
- 150 Pages
Global
From €4597EUR$4,850USD£3,840GBP
- Report
- February 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- August 2024
- 200 Pages
Global
From €4691EUR$4,949USD£3,919GBP
- Report
- October 2024
- 183 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- March 2023
- 64 Pages
Global
From €2370EUR$2,500USD£1,980GBP
- Report
- September 2023
- 374 Pages
Global
From €4692EUR$4,950USD£3,920GBP
- Report
- May 2022
- 228 Pages
Global
From €2488EUR$2,625USD£2,079GBP
€4976EUR$5,250USD£4,157GBP
- Report
- September 2021
- 262 Pages
Global
From €3554EUR$3,750USD£2,969GBP

The Subcutaneous Immunoglobulin (SCIg) market is a segment of the Immune Disorders Drugs market. SCIg is a form of immunoglobulin therapy used to treat a variety of immune-mediated diseases, such as primary immunodeficiencies, autoimmune diseases, and chronic inflammatory diseases. SCIg is administered through subcutaneous injections, which are less painful and more convenient than intravenous infusions. SCIg is also more cost-effective than intravenous immunoglobulin (IVIg).
SCIg is a rapidly growing market, driven by the increasing prevalence of immune-mediated diseases and the growing demand for more convenient and cost-effective treatments. The market is expected to continue to grow in the coming years, as more patients are diagnosed with immune-mediated diseases and as new treatments become available.
Some of the major players in the SCIg market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more